Terms: = Lymphoma AND COL2A1, SEDC, MGC131516, COL11A3, AOM, ANFH, ENSG00000139219, 1280 AND Prognosis
4 results:
1. The expression and clinical significance of PLK1/p-PLK1 protein in NK/T cell lymphoma.
Zhang Z; Liu E; Zhang D; Zhao W; Wang G; Zhang Y; Huo Y; Zhang C; Li W
Diagn Pathol; 2023 Nov; 18(1):129. PubMed ID: 38037110
[TBL] [Abstract] [Full Text] [Related]
2. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.
Poeschel V; Held G; Ziepert M; Witzens-Harig M; Holte H; Thurner L; Borchmann P; Viardot A; Soekler M; Keller U; Schmidt C; Truemper L; Mahlberg R; Marks R; Hoeffkes HG; Metzner B; Dierlamm J; Frickhofen N; Haenel M; Neubauer A; Kneba M; Merli F; Tucci A; de Nully Brown P; Federico M; Lengfelder E; di Rocco A; Trappe R; Rosenwald A; Berdel C; Maisenhoelder M; Shpilberg O; Amam J; Christofyllakis K; Hartmann F; Murawski N; Stilgenbauer S; Nickelsen M; Wulf G; Glass B; Schmitz N; Altmann B; Loeffler M; Pfreundschuh M; ;
Lancet; 2019 Dec; 394(10216):2271-2281. PubMed ID: 31868632
[TBL] [Abstract] [Full Text] [Related]
3. Prognostic impact of serum soluble interleukin-2 receptor level at diagnosis in elderly patients with diffuse large B-cell lymphoma treated with R-CHOP.
Umino K; Fujiwara SI; Minakata D; Yamamoto C; Meguro A; Matsuyama T; Sato K; Ohmine K; Izumi T; Muroi K; Kanda Y
Leuk Lymphoma; 2019 Mar; 60(3):734-741. PubMed ID: 30188236
[TBL] [Abstract] [Full Text] [Related]
4. Discordant response to chemotherapy: an unusual pattern of fluoro-deoxy-D-glucose uptake in heavily pre-treated lymphoma patients.
Alinari L; Ambrosini V; Castellucci P; Tani M; Stefoni V; Nanni C; Farsad M; Rubello D; Franchi R; Zinzani PL; Fanti S
Leuk Lymphoma; 2006 Jun; 47(6):1048-52. PubMed ID: 16840196
[TBL] [Abstract] [Full Text] [Related]
